Validations: Potency/Identity & Complex CQAs
Matrix Effects and Interferences: Mitigation Strategies Introduction to Matrix Effects and Interferences in Biologics Biopharmaceutical development, particularly within the realms of Advanced Therapy Medicinal Products (ATMP) and other biologics, necessitates a profound understanding of matrix effects and their corresponding interferences. Matrix effects can significantly influence analytical results, especially during viral clearance validation and potency assessments. Understanding and mitigating these interferences…
Assay Variability & Gage R&R: What’s Acceptable Assay Variability & Gage R&R: What’s Acceptable Understanding Assay Variability in Pharmaceutical Validation Assay variability is a crucial concept in the validation of biologics, primarily because it helps in understanding the precision and reliability of analytical methods used in the evaluation of potency and identity of complex quality attributes (CQAs) in Advanced Therapy…
Bridging Assays Across Sites: Equivalence and Bias Bridging Assays Across Sites: Equivalence and Bias In the rapidly evolving realm of pharmaceuticals, particularly within the context of biologics and advanced therapy medicinal products (ATMPs), ensuring consistency and reliability in assay performance across different sites is paramount. This article discusses bridging assays across different clinical sites by emphasizing the importance of equivalence…
Complex CQAs in Biologics/ATMP: Potency, Identity, and Purity Complex CQAs in Biologics/ATMP: Potency, Identity, and Purity As the landscape of biologics and Advanced Therapy Medicinal Products (ATMP) evolves, so does the complexity of their Critical Quality Attributes (CQAs). This article serves as a comprehensive guide for professionals involved in the development and regulation of these complex products, specifically focusing on…
Complex CQAs in Biologics/ATMP: Potency, Identity, and Purity Complex CQAs in Biologics/ATMP: Potency, Identity, and Purity In the realm of pharmaceuticals, particularly with Biologics and Advanced Therapy Medicinal Products (ATMPs), the critical quality attributes (CQAs) surrounding potency, identity, and purity have become increasingly complex. Regulatory guidelines such as ICH Q5A(R2), FDA process validation requirements, and the new aseptic controls outlined…
Potency Assays: Cell-Based vs Binding—Which and Why In the realm of biotechnology and pharmaceuticals, potency assays play a crucial role in ensuring the efficacy and safety of biologics and advanced therapy medicinal products (ATMPs). As regulatory agencies such as the FDA, EMA, and MHRA increasingly scrutinize these methods, understanding the distinctions between cell-based assays and binding assays is fundamental for…
Potency Assays: Cell-Based vs Binding—Which and Why Introduction to Potency Assays in Biologics Validation In the realm of biopharmaceutical development and manufacturing, the validation of potency assays is a critical component, particularly when engaging with advanced therapeutic medicinal products (ATMPs) and biologics. Potency assays serve as key quality control mechanisms to assess a product’s therapeutic efficacy and ensure consistent performance…
Identity Testing: Sequencing, Proteomics, and Flow Cytometry Identity Testing: Sequencing, Proteomics, and Flow Cytometry Introduction to Identity Testing in Biologics Identity testing is a fundamental aspect of the validation process for biologics and advanced therapy medicinal products (ATMP). It encompasses various methodologies and technologies including sequencing, proteomics, and flow cytometry. The validation of identity is critical as it assures product…